 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2012;5(4):310-315
Review Article
BRAF mutation in papillary thyroid carcinoma
Xinying Li, Asim B Abdel-Mageed, Emad Kandil
Department of Surgery, Tulane University, School of medicine, New Orleans, LA; Department of General Surgery, Xiangya Hospital,
Central South University, Changsha, China; Department of Pharmacology, Tulane cancer center, Tulane University School of Medicine,
New Orleans, LA, USA.
Received May 25, 2012; accepted July 11, 2012; Epub August 22, 2012; Published September 15, 2012
Abstract: BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC).
Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development
of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of
the BRAF mutation alternation in PTC. Detection of BRAF mutation on FNA specimen before surgery is recommended as a useful
diagnostic marker and prognostic indicator for PTC, and thus influences surgeon’s decision on management of PTC. Recent studies
have focused on inhibition of BRAF activation and several small molecules have been developed as targeting therapy. (IJCEM1205006).
Keywords: BRAF mutation, papillary thyroid carcinoma, BRAF/MAPK signaling pathway, targeting therapy
Address all correspondence to:
Emad Kandil, MD
Department of Surgery
Tulane University School of Medicine
1430 Tulane Avenue, Room 8510 (Box SL-22)
New Orleans, LA 70112, USA.
TeL:(504) 988-7520; Fax: (504) 988-4762
E-mail: ekandil@tulane.edu
Review Article
BRAF mutation in papillary thyroid carcinoma
Xinying Li, Asim B Abdel-Mageed, Emad Kandil
Department of Surgery, Tulane University, School of medicine, New Orleans, LA; Department of General Surgery, Xiangya Hospital,
Central South University, Changsha, China; Department of Pharmacology, Tulane cancer center, Tulane University School of Medicine,
New Orleans, LA, USA.
Received May 25, 2012; accepted July 11, 2012; Epub August 22, 2012; Published September 15, 2012
Abstract: BRAF mutation is the most common genetic alternation in thyroid cancer, particularly in papillary thyroid cancer (PTC).
Excessive activation of BRAF/MAPK signaling pathway due to BRAF mutation plays a central role in the tumorigenesis and development
of PTC. The association of BRAF mutation with poor clinicopathological characteristics of PTC further demonstrated the importance of
the BRAF mutation alternation in PTC. Detection of BRAF mutation on FNA specimen before surgery is recommended as a useful
diagnostic marker and prognostic indicator for PTC, and thus influences surgeon’s decision on management of PTC. Recent studies
have focused on inhibition of BRAF activation and several small molecules have been developed as targeting therapy. (IJCEM1205006).
Keywords: BRAF mutation, papillary thyroid carcinoma, BRAF/MAPK signaling pathway, targeting therapy
Address all correspondence to:
Emad Kandil, MD
Department of Surgery
Tulane University School of Medicine
1430 Tulane Avenue, Room 8510 (Box SL-22)
New Orleans, LA 70112, USA.
TeL:(504) 988-7520; Fax: (504) 988-4762
E-mail: ekandil@tulane.edu
